ActiTrexx

Executive Summary

ActiTrexx is a Munich-based biotechnology company developing novel therapies based on activated regulatory T cells (Tregs) to restore immune tolerance in patients with autoimmune and autoinflammatory diseases. Founded in 2010, the company aims to address the root causes of dysfunctional immune responses by leveraging the natural immunomodulatory properties of Tregs. ActiTrexx's platform focuses on isolating, activating, and expanding patients' own Tregs ex vivo before reinfusion, potentially offering a durable therapeutic option for conditions such as type 1 diabetes, rheumatoid arthritis, and graft-versus-host disease. Although the company remains in early stages with disclosed preclinical or clinical milestones, its proprietary technology and clear unmet medical need position it as a promising player in the cell therapy space. The German biotech ecosystem and supportive regulatory environment further enhance its potential for future growth and collaboration opportunities with larger pharmaceutical partners.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program30% success
• Q3 2026Series A Financing Round50% success
• Q2 2026Publication of Preclinical Efficacy Data60% success